[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344651-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344651-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","role-of-tumor-infiltrating-lymphocytes-and-mir-155-in-breast-cancer-insights-into-carcinogenesis-and-their-potential-as-prognostic-biomarkers","Role of tumor-infiltrating lymphocytes and miR-155 in breast cancer - Insights into carcinogenesis and their potential as prognostic biomarkers","","Breast cancer remains the most common cancer among women worldwide. This review analyzes breast cancer biology, highlighting the interplay between tumor-infiltrating lymphocytes (TILs) and microRNAs. TILs mirror immune activity and correlate with more favorable prognoses and therapy response. Lymphocyte-predominant patterns and specific infiltration thresholds are discussed, alongside regulation of the inflammatory tumor microenvironment by miR-155. The review also links miR-155 to immune cell subsets, signaling pathways, and potential clinical biomarker use. It emphasizes integrated, personalized biomarker strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/role-of-tumor-infiltrating-lymphocytes-and-mir-155-in-breast-cancer-insights-into-carcinogenesis-and-their-potential-as-prognostic-biomarkers/344651/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/role-of-tumor-infiltrating-lymphocytes-and-mir-155-in-breast-cancer-insights-into-carcinogenesis-and-their-potential-as-prognostic-biomarkers/344651.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do tumor-infiltrating lymphocytes (TILs) relate to breast cancer prognosis and treatment response?","Question",{"text":63,"@type":64},"TILs reflect immune system activity against tumors and are associated with more favorable prognoses and positive response to therapies. Elevated TIL levels characterize lymphocyte-predominant breast cancers with higher therapeutic response rates.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the role of miR-155 in shaping the tumor inflammatory microenvironment?",{"text":68,"@type":64},"miR-155 helps regulate the tumor inflammatory landscape and is linked to the presence of TILs and a favorable inflammatory profile. It is associated with multiple antitumoral immune cells while showing negative associations with pro-tumoral regulatory T cells and M2 macrophages.",{"name":70,"@type":61,"acceptedAnswer":71},"How could TIL and miR-155 thresholds be used clinically as biomarkers?",{"text":72,"@type":64},"The review discusses that higher TIL levels (e.g., ≥50%) relate to pathological complete response and long-term survival, while a lower threshold (around 30%) can still predict favorable prognosis and identify a broader patient group. Serum miR-155 levels in patients align with tumor miR-155 and immune status, supporting biomarker potential.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344651,1790437180,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":99,"preview_page_count":33,"preview_urls":145},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","ONCOLOGY REPORTS 55: 42, 2026  \nRole of tumor‑infiltrating lymphocytes and miR‑155 in breast cancer: Insights into carcinogenesis and their potential as prognostic biomarkers (Review)  \nMIRIAM MONTEIRO ALVARES‑VILELA 1‑3 , FRANCIELE SCHLEMMER 1,2 ,  \nSABRINA SIMPLÍCIO DEARAÚJO ROMERO FERRARI 1,2 , MARY‑ANN ELVINA XAVIER 1,2 and RICARDO TITZE‑DE‑ALMEIDA 1,2  \n1Technology for Gene Therapy Laboratory, Central Institute of Sciences, University of Brasília, Brasília 70910‑900, Brazil; 2  \nResearch Center for Major Themes‑Breast Cancer Unit, Central Institute of Sciences, University of Brasília, Brasília 70910‑900, Brazil; 3Hospital de Base of The Federal District, Brasília 70330‑150, Brazil  \nReceived March 14, 2025; Accepted May 9, 2025  \nDOI: 10. 3892/or.2026.9047  \nAbstract. Breast cancer is the most common cancer in the female population worldwide. The present review examines the biology of breast cancer, with a focus on the interplay between tumor‑infiltrating lymphocytes (TILs) and microRNAs (miRNAs or miRs) . TILs, which reflect the immune system activity in combating tumors, are associated with more favorable prognoses and positive response to therapies . Elevated levels of TILs characterize lymphocyte‑predominant breast cancers (LPBCs), which are associated with higher therapeutic response rates in triple‑negative breast cancer, a type of LPBC. Defining the threshold for LPBCs presents a challenge: TIL levels ≥50% are associated with short‑term pathological complete response as well as long‑term overall and disease‑free survival; however, this percentage is not often achieved in clinical practice. Conversely, a lower threshold of 30% lymphocyte infiltration can predict favorable prognosis for anticancer therapy and allows for the identification of abroader range of patients. The tumor inflammatory landscape is regulated by miRNAs, particularly miR‑155. Elevated levels of miR‑155 are associated with the presence of TILs and a favorable inflammatory profile, leading to a tumor‑inflamed microenvironment. Moreover, miR‑155 is associated with various antitumoral immune cells, including CD8+ T cells and M1 macrophages, but negatively associated with pro‑tumoral regulatory T cells and M2 macrophages . Overexpression  \nCorrespondence to: Professor Ricardo Titze‑de‑Almeida or Dr Mary‑Ann Elvina Xavier, Research Center for Major Themes‑Breast Cancer Unit, Central Institute of Sciences, University of Brasília, Campus Universitário Darcy Ribeiro, 605 North, Gleba A, Brasília 70910‑900, Brazil  \nE‑mail: [ricardotitze.unb@gmail.com](ricardotitze.unb@gmail.com)  \nE‑[mail: maryhorsann@gmail.com](mail: maryhorsann@gmail.com)  \nKey words: tumor‑infiltrating lymphocyte, biomarker, microRNA‑155, triple‑negative breast cancer  \nof miR‑155 results in an increase in the levels of the C‑X‑C chemokine ligands, constituted by two conserved cysteines separated by a different amino acid which bind to the same chemokine receptor CXC chemokine receptor 3. These results in activation of T cells a process that involves the inhibition of suppressor of cytokine signaling 1 and an elevated ratio of phosphorylated STAT1/STAT3 . Additionally, miR‑155 affects key signaling pathways, including the PI3K/AKT and IL‑6/STAT3 pathways, and increases sensitivity to immune checkpoint blockade therapy. In clinical samples from patients with BC, serum levels of miR‑155 align with both tumor miR‑155 levels and the immune status of the tumor. The present review emphasizes the importance of understanding the dynamics between TILs and miRNAs to identify new prog‑ nostic and predictive biomarkers, proposing a more integrated and personalized approach in the management of BC.  \nContents  \n1. Introduction  \n2. BC biology and classification  \n3. Tumor‑infiltrating lymphocytes (TILs) in breast cancer  \n4. Clinically relevant cut‑off values for TILs in pre‑neoadju‑ vant biopsy samples  \n5. miR‑155 and TIL activity  \n6. Translating scientific findings into clinical practice","cbCaiofJsCmOZPWR","https://ap.wps.com/l/cbCaiofJsCmOZPWR","pdf",5591169,24,"English","# Contents\n## 1. Introduction\n## 2. BC biology and classification\n## 3. Tumor-infiltrating lymphocytes (TILs) in breast cancer\n## 4. Clinically relevant cut-off values for TILs in pre-neoadju-vant biopsy samples\n## 5. miR-155 and TIL activity\n## 6. Translating scientific findings into clinical practice and limitations\n## 7. Conclusion","[{\"question\":\"How do tumor-infiltrating lymphocytes (TILs) relate to breast cancer prognosis and treatment response?\",\"answer\":\"TILs reflect immune system activity against tumors and are associated with more favorable prognoses and positive response to therapies. Elevated TIL levels characterize lymphocyte-predominant breast cancers with higher therapeutic response rates.\"},{\"question\":\"What is the role of miR-155 in shaping the tumor inflammatory microenvironment?\",\"answer\":\"miR-155 helps regulate the tumor inflammatory landscape and is linked to the presence of TILs and a favorable inflammatory profile. It is associated with multiple antitumoral immune cells while showing negative associations with pro-tumoral regulatory T cells and M2 macrophages.\"},{\"question\":\"How could TIL and miR-155 thresholds be used clinically as biomarkers?\",\"answer\":\"The review discusses that higher TIL levels (e.g., ≥50%) relate to pathological complete response and long-term survival, while a lower threshold (around 30%) can still predict favorable prognosis and identify a broader patient group. Serum miR-155 levels in patients align with tumor miR-155 and immune status, supporting biomarker potential.\"}]","Role of tumor-infiltrating lymphocytes and miR-155 in breast cancer - Insights into carcinogenesis and their potential as prognostic biomarkers | PDF",1790054763,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73da1e72f6fb8e8dcbaa47cea0b736f5.webp",983,1357,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6e0d14871533246ac52078eb51741bc.webp",982,1356,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d37ad19ad8e8e425fce97ab24983e5c7.webp",981,1354,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60719f05bcdc29976c28b4baa037630c.webp",980,1353]